Charles River Associates (CRA) Expands Global Life Sciences Offering
River Associates (NASDAQ: CRAI), a worldwide leader in providing
economic, and financial consulting services, today announced that
Beards has joined the firm as a vice president in the
Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing management, economic, and financial consulting services, today announced that Mark Beards has joined the firm as a vice president in the Life Sciences Practice based in London. Mr. Beards most recently led European healthcare equity research at Goldman Sachs in London. Prior to that, he was a consultant at McKinsey & Company and worked in commercial and research roles at leading, global pharmaceutical companies. “Mark Beards’ expansive background—as an equity analyst in capital markets covering European life sciences companies, a strategy consultant advising large cap pharmaceutical organizations, and a business manager with direct sector experience—makes him a valuable addition to CRA,” said CRA's President and Chief Executive Officer Paul Maleh. “His deep knowledge base and practical approach allow for advising and problem-solving on a range of issues confronting life sciences companies. It is a pleasure to welcome him to CRA, where he will play an important role within our global life sciences offering.” Mr. Beards has 20 years of experience in the life sciences and financial sectors. His specialties include commercialization, R&D, licensing, and setting corporate and product strategy. He has transformed underperforming business units into highly successful ones; developed licensing strategies to direct business development priorities; led due diligence, negotiations, and deal structures for licensing agreements; constructed go-to market strategies; and redesigned global marketing functions. In his most recent role at Goldman Sachs, Mr. Beards was Vice President, Head of Equity Research, European Healthcare, and was responsible for coverage of the pharmaceutical, medical technology, and biotechnology sectors. He was the primary analyst on diversified pharmaceutical companies with a combined market capitalization of $335 billion. At McKinsey & Company, he focused on life sciences and advised global pharmaceutical companies in such areas as corporate strategy development, corporate transformation, product launch strategy, distribution valuation, consumer segmentation, and brand positioning. Prior to this role, Mr. Beards spent 11 years in business development and commercial strategy roles at Abbott Laboratories and GlaxoSmithKline, respectively. He began his career as an accountant and is a Chartered Management Accountant, ACMA. He holds a Diploma in Business Management from Henley Management College and a BA (Hons) degree and an MA degree in Mathematics from The Queen’s College, Oxford.
Shares of CRA International (Nasdaq:CRAI) have taken a tremendous swing upward. The stock is trading at $24.92 as of 11:21 a.m. ET, 23.4% above Wednesday's closing price of $20.19. Volume is at 20,984, 0.5 times the daily average of 40,100.